Truist Securities Reiterates Buy Rating on PTC Therapeutics (PTCT)

August 19, 2025 11:01 AM EDT Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $86.00 price target on PTC Therapeutics (NASDAQ: PTCT).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login